Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 50,05 € (+16,88 %). Medianen er 50,50 € (+17,94 %).
| Køb |
5 |
| Behold |
1 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
HeartFlow: plaque analysis becomes main growth driver
HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Mere på de.investing.com
Heartflow climbs to new record high of $51.26
Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Mere på de.investing.com
Heartflow hits record high of $48.70 after strong Q2 results
Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Mere på de.investing.com
HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours
HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » Mere på de.investing.com
HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker
HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 64,32 mio. | 63,12 % |
| Bruttofortjeneste | 53,78 mio. | 78,21 % |
| Nettoresultat | -10,16 mio. | 76,56 % |
| EBITDA | -10,13 mio. | 73,74 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 3,73 mia. € |
Antal aktier | 87,89 mio. |
Højeste/laveste i 52 uger | 55,20 € - 18,32 € |
| Udbytte | Nej |
Beta | 2,02 |
P/E (PE Ratio) | -50,70 |
PEG (PEG Ratio) | -0,81 |
K/I (PB Ratio) | 14,40 |
P/S (PS Ratio) | 17,18 |
Virksomhedsprofil
HeartFlow, Inc., et medicinteknologisk selskab, leverer non-invasive løsninger til diagnosticering og behandling af koronare hjertekarsygdomme over hele verden. Dets HeartFlow Platform bruger AI og beregningsmæssig væskedynamik (computational fluid dynamics) til at skabe en personlig 3D-model af en patients hjerte ud fra en enkelt koronar computertomografi-angiografi, en specialiseret type scanning, der giver detaljerede billeder af hjertets arterier. Selskabets platform giver indsigt i blodgennemstrømning, stenose og plaquevolumen og -sammensætning ved at overvinde begrænsningerne ved traditionelle non-invasive billeddiagnostiske undersøgelser. Selskabet blev grundlagt i 2007 og har hovedkontor i Mountain View, Californien.
| Navn | HeartFlow |
| CEO | John Farquhar |
| Websted | |
| Børsnotering | 07.08.2025 |
| Medarbejdere | 843 |